Program
4CMenB vaccine
Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.
In GlaxoSmithKline’s pipeline, Recombinant protein and outer membrance vesicle vaccine
. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 130 open or running | phase 3since Apr 2, 2008 | Feb 27, 2006 | none ahead |
| Pfizerits history only | 90 open or running | phase 4since May 14, 2021 | Oct 11, 2006 | none ahead |
| GlaxoSmithKline | 71 open or running | phase 4since Feb 6, 2018 | Feb 14, 2014 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Sep 4, 2019 | Sep 4, 2019 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
Men B vaccine GSK3536829
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2014First study: phase 3 study in Meningococcal InfectionsFirst studyNCT02106390 · 750 enrolled · Argentina, Mexico
- Jun 5, 2014Phase 3 study in Meningococcal InfectionsNCT02173704 · 225 enrolled · Taiwan
- Aug 6, 2014Phase 2 study in Meningococcal InfectionsNCT02212457 · 1,063 enrolled · United States, Finland, Poland
- Feb 6, 2018Phase 4 study in Meningitis, MeningococcalNCT03493919 · 1,021 enrolled · Australia, Germany
- Aug 4, 2020Phase 3 study in Meningococcal InfectionsNCT04502693 · 3,657 enrolled · United States, Australia, Canada and more
- Oct 27, 2023Phase 4 study in Meningitis, MeningococcalNCT06113198 · 50 enrolled · South Korea
- May 20, 2025Phase 3 study in MeningitisNCT06995430 · 312 enrolled · Finland, Italy, Spain and more
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule
Studies
All 7 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06995430Meningitis · Finland, Italy, Spain and more | 3 | Completed | Dec 15, 2025 | 312 |
| NCT06113198Meningitis, Meningococcal · South Korea | 4 | Active, not recruiting | Sep 7, 2026 | 50 |
| NCT04502693Meningococcal Infections · United States, Australia, Canada and more | 3 | Completed | Sep 13, 2022 | 3,657 |
| NCT03493919Meningitis, Meningococcal · Australia, Germany | 4 | Completed | May 27, 2022 | 1,021 |
| NCT02212457Meningococcal Infections · United States, Finland, Poland | 2 | Completed | May 22, 2015 | 1,063 |
| NCT02173704Meningococcal Infections · Taiwan | 3 | Completed | Dec 25, 2015 | 225 |
| NCT02106390Meningococcal Infections · Argentina, Mexico | 3 | Completed | Oct 14, 2016 | 750 |
How it is read
Names in the registry
- “rLP2086”, 11 entries
- “rMenB+OMV NZ”, 9 entries
- “Meningococcal B vaccine”, 6 entries
- “rMenB+OMV NZ vaccine”, 3 entries
- “Meningococcal group B vaccine”, 3 entries
Conditions, from the studies’ own filings
- Meningococcal Infections, 10 studies
- Meningitis, Meningococcal, 9 studies
- Meningitis, 2 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.